[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:volunteers":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,71,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100365618","influence-of-screen-sizes-on-responses-to-visual-analog-scales-of-stress-100365618",false,"NCT04040608","Influence of Screen Sizes on Responses to Visual Analog Scales of Stress","SIVAStress","Inclusion Criteria:\n\n* Adult persons\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Unable to answer basic questions (difficulties understanding, cognitive disorders…)",true,"ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Visual analog scales (VAS) are one of the most common tools used in questionnaires. VAS are validated for pain and stress for example on a horizontal, non-calibrated line of 100 mm, ranging from very low (0) to very high (100). Nowadays, most VAS are used on questionnaires on internet. However, the influence of screen sizes on responses to visual analog scales were never studied.",[25],"Volunteers",[27,28],"visual analog scale","stress","RECRUITING","2026-02-11",{"date":32,"type":33},"2026-02-12","ACTUAL",{"date":35,"type":33},"2021-03-02",{"date":37,"type":21},"2028-03",{"name":39,"class":40},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100617470","breathlessness-patterns-in-patients-with-cancer-copd-and-heart-failure-an-fmri-feasibility-study-100617470","NCT07319039","Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study","BREACH-fMRI","Inclusion Criteria\n\n* Age ≥ 18 years and\n* Followed by the outpatient palliative care clinic of the Geneva University Hospitals, Switzerland (HUG) and\n* Breathlessness at rest \\> 2 and \\\u003C 8 on the NRS (numeric rating scale 0 to 10) and\n* Persistent breathlessness (persistent dyspnea for \\> 3 weeks despite adequate and maximal medication according to the pathology) and\n* In a stable clinical condition, i.e., without an episode of acute cardiac, respiratory, and\u002For neurological failure leading to hospitalization in the previous 4 weeks and\n* Diagnosis of either HF stage NYHA III-IV, or COPD with dyspnea on the modified MRC scale grade 3-4, or oncological disease with primary or secondary pulmonary involvement\n\nInclusion Criteria for Healthy Volunteers (Control Group)\n\n* Age ≥ 18 years and\n* No respiratory symptoms: dyspnea, cough, wheezing and\n* No known pulmonary, cardiac, or oncological disease and\n* Smoking status \\\u003C 10 pack-years and\n* No contraindication to fMRI (Appendix 3) and\n* Ability to lie flat (supine position) and\n* No diagnosed psychiatric illness (severe depression, severe anxiety, psychosis, other) or antipsychotic treatment deemed a contraindication for fMRI based on physician judgement and\n* No neurological disorders according to neurological assessment, including diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.), or epilepsy and\n* No claustrophobia, acrophobia, photophobia, severe hearing loss, and\u002For severe visual deficit and\n* No contraindication to IVR (migraines, photosensitive epilepsy, vertigo)\n\nExclusion Criteria\n\n* Breathlessness at rest ≥ 8 on the NRS (numeric rating scale 0 to 10)\n* Contraindication to fMRI\n* Inability to lie flat (supine position)\n* Diagnosed psychiatric illness (severe depression, severe anxiety, psychosis, other) or antipsychotic treatment deemed a contraindication for fMRI based on physician judgement\n* Neurological disorders according to neurological assessment, including diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.), or epilepsy\n* Presence of claustrophobia, acrophobia, photophobia, severe hearing loss, and\u002For severe visual deficit\n* Contraindication to IVR (migraines, photosensitive epilepsy, vertigo)",{"count":50,"type":21},16,"Dyspnea that persists despite optimal pathophysiological treatment is defined as persistent dyspnea.\n\nCurrently all brain functional magnetic resonance imaging (fMRI) studies conducted to evaluate breathlessness have done so using healthy volunteers or have concentrated on acute breathlessness. Little is known about chronic breathlessness patterns and their modulation by different triggers. Furthermore, it is currently assumed in the palliative care literature that patients suffering from different advanced and progressive diseases such as cancer, heart failure (HF) or chronic obstructive pulmonary disease (COPD) have the same triggers, perceptions and neurological pathways and thus require the same treatments\u002Finterventions (i.e. opioids as first line symptomatic pharmacologic treatment). However, it is now known that patients belonging to different disease groups do not necessarily benefit from opioids.\n\nAim of the study To assess the feasibility of identifying dyspnea patterns in different life-limiting conditions and to evaluate the effect of immersive virtual reality (IVR) on dyspnea using patient-reported-outcomes (PROMs).\n\nStudy procedure:\n\nPatients with advanced chronic diseases such as cancer, COPD or HF suffering from dyspnea will undergo a brain fMRI in combination with an IVR intervention. The fMRI data will be reviewed to identify different patterns of dyspnea and the effect of IVR on dyspnea will be assessed through PROMs. Patients will be asked about the perceived burden of the study.",[53,54,55,25],"Chronic Obstructive Pulmonary Disease (COPD)","Heart Failure","Cancer",[57,58,59,60,61],"Persistent dyspnea","Breathlessness","Palliative Medicine","Cerebral fMRI","Immersive virtual reality","2026-01-06",{"date":64,"type":33},"2026-01-08",{"date":66,"type":33},"2025-08-26",{"date":68,"type":21},"2027-03-01",{"name":70,"class":40},"University Hospital, Geneva",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100619156","valid-bwell-bp25-study-100619156","NCT07340957","Valid-B.Well BP25 Study","Validation of the B. Well Digital Upper Arm Blood Pressure Monitor Pro-25 According to ISO 81060- 2","Inclusion Criteria:\n\n* Age \\> 12 years\n* Signed Informed Consent\n\nExclusion Criteria:\n\n* Any medical condition preventing light to moderate arm compression\n* Absence of the upper arm\n* Subjects with upper arm circumference \\\u003C22 cm or \\>42 cm\n* Subjects with severe shock;\n* Subjects with a history of mental illness or current mental disorders;\n* Patients with arrhythmias (atrial premature beats, ventricular premature beats, atrial fibrillation, etc.) or upper limb arteriosclerosis (at the direct measurement site);\n* Subjects using extracorporeal circulation devices;\n* Subjects with excessive limb asymmetry;\n* Subjects who have undergone mastectomy or lymph node dissection;\n* Subjects with arm injuries or exposed wounds, or those with circulatory disorders;\n* Subjects with vascular accesses in the arms or arteriovenous shunt tubes;\n* Subjects who have participated in other clinical trials within the past 1 month;\n* Subjects for whom the procedures during the clinical trial may pose excessive medical risks;\n* Subjects determined by the investigator to be unsuitable for participating in the clinical study.\n* Subject under judicial protection, guardianship or curatorship or participant deprived of their liberty by judicial or administrative decision","12 Years",{"count":80,"type":21},100,"INTERVENTIONAL",[83],"NA","Prospective, single-center, single-arm, open, comparative, validation of a commercialized device, repeated measures accuracy study designed in accordance with the requirements of the ISO 81060-2:2018 AAMI\u002FESH\u002FISO Universal Standard for the clinical validation of automated non-invasive sphygmomanometers (Non-invasive sphygmomano-meters - Part 2: Clinical investigation of intermittent automated measurement, including Amendments 1 and 2)).\n\nThe validation will be conducted with volunteers rather than necessarily with patients, and all measurements will be performed outside of the subjects' normal diagnosis or treatment.",[25,86],"Study Focus: Blood Pressure Measures",[88,89,90,91],"blood pressure","iso 81060-2","upper arm blood pressure monitor","commercialized device validation","NOT_YET_RECRUITING","2026-01-05",{"date":95,"type":33},"2026-01-14",{"date":97,"type":21},"2026-01",{"date":99,"type":21},"2026-03",{"name":101,"class":102},"B.Well Swiss AG","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":41},"100382184","cardiometabolic-health-and-inflammatory-resolution-100382184","NCT04256330","Cardiometabolic Health and Inflammatory Resolution","Cardiometabolic Health and Inflammatory Resolution (Kardiometabol hälsa Och Inflammatorisk Resolution)","REX","Inclusion Criteria:\n\n* Informed signed consent has been obtained from the volunteer.\n* The volunteer has a BMI greater than 18.5 kg\u002Fm2\n\nExclusion Criteria:\n\n* The study staff contacting a potential participant perceives that the individual has difficulty understanding the information.\n* An MD determines that the individual is on too many medications to participate\n* The individual takes a medication that is approved by the MD, but he\u002Fshe is not willing or not able to wait with any potential morning medication until after their fasted blood-draw.\n* The individual is younger than 18 years (relevant for the FAINT-1 and FAINT-2 cohorts)\n* The individual states that they have increased bleeding tendency or are using anti-coagulant (blood thinning) medication.\n* The individual has some form of chronic inflammation.\n* The individual regularly uses medication that affects inflammatory resolution (e.g., low-dose aspirin).\n* The individual uses immunosuppressive drugs (eg, methotrexate).\n* The individual regularly consumes fish oils (omega 3).\n* The individual has significant gastrointestinal problems.\n* The individual smokes or uses chewing tobacco.\n* The individual has been drinking alcohol two days before the study visit.\n* The individual has tattoos or body piercings on the forearms and \u002F or the stomach that can affect the examination.\n* The individual does not follow instructions given in the research study.","65 Years",{"count":20,"type":21},"The aim of this study is to determine how inflammatory resolution impacts cardiometabolic health and disease in subjects that are either lean (18.5-24.9 kg\u002Fm2), overweight (25.0-29.9 kg\u002Fm2) or obese (\\>30.0 kg\u002Fm2).",[25],"2025-05-05",{"date":117,"type":33},"2025-05-08",{"date":119,"type":33},"2020-01-23",{"date":121,"type":21},"2027-09-01",{"name":123,"class":40},"Göteborg University"]